MassHealth 340B Drug Exclusion Report

This bill requires MassHealth (Massachusetts' Medicaid program) to submit an annual report on how 340B drugs impact high-cost medication spending. The report, mandated under Section 13L of Chapter 118E, details program costs, drug utilization patterns, and the financial effects of excluding 340B drugs from reimbursement. It directly affects MassHealth administrators and state health officials who use the data for program oversight. This is a procedural reporting requirement under existing law, not a policy change.